Lilly starts construction of $3.5bn obesity-medicine plant in Pennsylvania
- The facility is expected to create 850 permanent jobs and about 2,000 construction jobs.
- The Fogelsville site is expected to be operational by 2031.
- It is one of four injectable-medicine and device sites among 10 U.S. manufacturing sites Lilly has announced since 2020.
- Retatrutide is an investigational GIP, GLP-1 and glucagon triple-receptor agonist being studied in Phase 3 trials.
Facility and production
Lilly has broken ground on a manufacturing facility in Fogelsville, Pennsylvania, to expand U.S. capacity for injectable medicines, including the investigational obesity treatment retatrutide. The site is expected to be operational by 2031 and is one of four injectable-medicine and device facilities among 10 U.S. sites announced by Lilly since 2020.
The company expects the project to create 850 jobs, including engineering, science, operations and laboratory roles, and about 2,000 construction jobs. The site is planned to use machine learning, artificial intelligence, digitally integrated systems, data analytics and automation. Lilly is targeting LEED Gold certification.
Retatrutide
Retatrutide is a single-molecule agonist of the GIP, GLP-1 and glucagon receptors. Lilly is evaluating it in Phase 3 trials for obesity and overweight with related health conditions, as well as several other indications. It is investigational and cannot be legally sold or marketed for human use.
Source: Lilly